Table 1 Baseline characteristics of the pediatric patients with HBeAg positive CHB
From: Prediction for HBsAg seroconversion in children with chronic hepatitis B
Variable | Overall (n = 63) | HBsAg seroconversion(n = 13) | Non-HBsAg seroconversion(n = 50) | P-value |
|---|---|---|---|---|
Age(years) | 5.48 ± 2.64 | 1.68 ± 0.71 | 6.47 ± 3.16 | 0.000 |
ALT > 2 × ULN, n(%) | 39(61.9) | 7(53.8) | 32(64.0) | 0.108 |
Serum HBV DNA (log10 IU/mL) | 7.39 ± 1.45 | 6.72 ± 1.52 | 7.56 ± 1.34 | 0.063 |
HBV cccDNA, (log10 copies/106 cell) | 6.64 ± 0.74 | 6.38 ± 0.79 | 6.79 ± 0.66 | 0.040 |
Serum HBsAg (log10 IU/mL) | 4.01 ± 0.86 | 3.48 ± 1.22 | 4.14 ± 0.69 | 0.009 |
Gender (n, %) | 0.208 | |||
Male | 34(54.0%) | 5(14.7%) | 29(85.3%) | |
Female | 29(46.0%) | 8(27.6%) | 21(72.4%) | |
HBV genotype (n, %) | 1.000 | |||
B | 16(25.4%) | 3(18.7%) | 13(81.3%) | |
C | 47(74.6%) | 10(21.3%) | 37(78.7%) | |
Grade of inflammation (n, %) | 0.082 | |||
G0–G1 | 30(47.6%) | 9(30.0%) | 21(70.0%) | |
≥ G2 | 33(52.4%) | 4(12.1%) | 29(87.9%) | |
Histological fibrosis stage (n, %) | 0.663 | |||
S0–S1 | 48(76.2%) | 11(22.9%) | 37(77.1%) | |
≥ S2 | 15(23.8%) | 2(13.3%) | 13(86.7%) |